Biocomposites, a medical device company that engineers, manufactures and markets products for use in infection management in bone and soft tissue, has signed an exclusive distribution agreement with NuVasive Specialized Orthopedics (NSO), an orthopaedic technology innovation company, to sell its STIMULAN products in Germany.
NSO, a subsidiary of NuVasive, is focussed on the design and innovation of orthopaedic and traumatological solutions.
Michael Harris, chief executive officer of Biocomposites, said: “Germany is Europe’s largest orthopaedic reconstruction market and is an important element of Biocomposites’ international growth strategy. NSO, with their impressive track record of delivering innovative treatments to patients and strong surgeon relationships, are the ideal partner to distribute STIMULAN to hospitals and surgeons treating infected and high-risk patients.”
Rob Martin, general manager of NSO, added: “NSO is excited to be the exclusive distributor for Biocomposites in the German market. The addition of a unique product like STIMULAN helps further differentiate our specialised orthopaedics portfolio to help drive continued value for our surgeons, providers, and patients in the region.”
STIMULAN is the only calcium matrix to receive a European CE mark approval for mixing with antibiotics: vancomycin, tobramycin, and gentamicin for use in bone and soft tissue. It offers surgeons the flexibility to apply a broad spectrum of ‘off-the-shelf’ antibiotics at the site of infection, at concentration levels unachievable systemically – which lowers rates of reinfection, saves cost, and improves patient outcomes.
STIMULAN is already used globally in over 50,000 cases every year and in thousands of hospitals around the world.
